• Two executives with near-term gold producer LaFleur Minerals recently appeared on CEO.CA’s Inside the Boardroom podcast to discuss activity at their Swanson Gold Deposit, in the globally recognized Abitibi Gold District of Quebec
• LaFleur is exploring approximately 18,304 hectares (45,230 acres) at Swanson, with the potential of expanding its land package to follow mineral structures crossing the site
• LaFleur is distinctive in that it has drilling infrastructure on site, a tailings facility, and a 750-metric-ton-capable mill for processing ore at its nearby Beacon Gold Mill, along with positive returns from its initial diamond drilling program at Swanson
• The company recently closed a fully subscribed equity offering, and is exploring other financing structures and additional opportunities as it completes a PEA and prepares for restart of its wholly owned mill that was idled by a previous owner following the post-pandemic gold plunge, offset now by gold’s record highs

Gold exploration and development company LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is on the cusp of realizing its verticals-driven strategy for mining and processing gold ore from its Swanson Gold Deposit in the prolific Abitibi Gold District of Quebec –  Canada’s largest gold producing district.

“There are two major structures that run through Swanson that host gold and even base metals,” LaFleur CEO Paul Ténière said during a recent interview with CEO.CA’s Inside the Boardroom podcast (https://ibn.fm/LYcjm).

LaFleur Minerals has drilled 24 holes to date on the approximately 18,304-hectare (45,230-acre), district-scale Swanson site. As of the end of September, six of the holes had been assayed and showed high-grade, near-surface intercepts, according to company statements. 

In a district where several gold projects are in process, LaFleur is excited about its prospects and anticipating its potential for growth. 

“We’ve done a pretty good job of consolidating originally around the Swanson deposit and have grown it to as it is,” Ténière told Inside the Boardroom’s host. “There are other opportunities, especially to the south and southeast of Swanson. … And so, what we’re looking at doing is consolidating and adding claims from adjacent properties into (Swanson) to continue to expand. And the good news with that is that once we consolidate, we also have a rig available that we can actually start drilling on right away. And some of (the) known gold showings and base metal showings are quite exciting.”

The company’s true strength is in the vertical integration of its own fully permitted and recently refurbished gold mill, tailings facility and its advanced exploration project and gold resource as source of material, positioning it competitively in the current high gold price environment. The company expects to use the mill for processing its ore in-house, but also anticipates the potential of contracting for custom milling work with a number of other nearby gold projects in need of such milling to drive near-term revenue. 

“We do need money to restart the mill,” LaFleur Chairman Kal Malhi acknowledged alongside Ténière during the interview. “We’re talking to several opportunities, either with royalty companies or forward sales of the gold production and that will hopefully bring in some very strong gold industry partners to the deal as well.” 

LaFleur completed a non-brokered private placement equity round last month and is also finalizing flow-through financing, bringing the company closer to 80 million shares, Malhi said. 

LaFleur also expects to wrap up a comprehensive Preliminary Economic Assessment (“PEA”) for Swanson around the end of October, which is led by reputable global consulting firm Environmental Resources Management (“ERM”) and brings a highly experienced technical team to deliver a robust mining and economic study for the restart of the Beacon Gold Mill using mineralized material primarily supplied from the company’s Swanson Gold Deposit.. Gold’s record prices topping $4,000 an ounce recently, in a remarkable comeback from 2022’s $1,600 level (https://ibn.fm/yGllm), are generating enthusiasm for the market and LaFleur’s verticals-driven strategy. 

“Our mill alone is valued at $70 million, our market cap now is about $42 (million)-$43 million. Again, the totality of the deal really is I think an exciting investment opportunity,” Malhi said. 

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

• ESGold Corp., a development stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, has inked a C$9 million binding term sheet with Ocean Partners UK Ltd.
• The facility bolsters the company’s financial position while affording it flexibility as it advances exploration on its Montauban facility
• The funds will be drawn in two tranches of C$3 million and C$6 million, respectively, both dependent on anticipated Phase 1 and Phase 2 production on the facility
• This validates the company’s strategy of advancing permitted, low-capex projects designed to generate high-margin returns while minimizing dilution

ESGold (CSE: ESAU) (OTCQB: ESAUF), an development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, just inked a C$9 million binding term sheet with Ocean Partners UK Ltd. This agreement bolsters the company’s financial position, while affording it flexibility as it continues to explore and advance its Montauban Gold-Silver Project in Quebec. It is an incredible milestone that guarantees a stable, long-term sales channel for all its gold and silver dore, while further creating certainty around revenue realization and reinforcing the project’s economic foundation (https://ibn.fm/lisS4).

The Montauban project boasts a rich mining history dating back to the early 1900s. Located just 80km west of Quebec City, this facility combines immediate revenue potential for ESGold with transformational exploration upside. So far, the company has invested over C$15 million in infrastructure, including power access, roads, and a 20,000 sq. ft. processing facility, demonstrating its confidence in the facility and its economic potential.

All permits for production are in place. Construction is underway, and on track to kick off production in 2026. The Ocean Partners funding commitment aims to make this a reality, while also providing an opportunity to generate cash flow without diluting its equity.

“This agreement with Ocean Partners is an important step forward for ESGold,” noted Gordon Robb, ESGold’s CEO.

“Ocean Partners’ support ensures that debt obligations will be serviced through operating cash flow rather than equity dilution, while establishing a stable long-term sales channel for the gold and silver dore produced from Montauban,” he added (https://ibn.fm/lisS4).

The C$9 million facility will be drawn in two tranches. The first, a C$3 million tranche, will be available three months before anticipated Phase 1 production, which is expected in February 2026. The second tranche of C$6 million will be available approximately five months before Phase 2 production, which is projected for March 2027. Its repayment will be made through dore deliveries in line with structured schedules per tranche, with Ocean Partners set to purchase 100% of the gold and silver dore from Montauban tailings and crown pillar material, subject to minimum deliveries of 50,000 oz of gold and 1,000,000 oz of silver.

“The Montauban project is exactly the type of innovative opportunity in which we like to be involved,” noted Brent Omland, Ocean Partners’ CEO. “ESGold has found an economically viable path forward for precious metal production from tailings and surface rock. We are very pleased to form a long-lasting partnership with the ESGold team and are excited about the long-term potential in this area of Quebec,” he added (https://ibn.fm/lisS4).

With this agreement, ESGold is now a fully funded company with the financial strength, strategic partnerships, and operational readiness to meet its 2026 Montauban production deadline. It also positions it ahead of competitors while further validating the company’s strategy of advancing permitted, low-capex projects designed to generate high-margin returns while minimizing dilution. As such, it points to ESGold’s future success as it firmly asserts its position as a leader in its space.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• The company reported a 1,508% increase in revenues from its IPP segment in FY 2025.
• Total company assets rose 253% year-over-year, driven by IPP expansion and strategic project acquisitions.
• Gross margin improved to 25% from 20% in FY 2024.
• The company announced up to US$100 million in project-based financing through a mandate with CIM Group.
• PowerBank’s development pipeline now totals 1,806 (MWdc, MWh) of solar PV and battery energy storage projects.
• CEO Dr. Richard Lu highlighted a transition toward long-term recurring revenue through asset ownership and financing.

Disseminated on behalf of PowerBank Corporation

PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., recently released its financial results for Fiscal Year 2025, which underscore a pivotal shift toward becoming a stable, asset-backed independent power producer (https://ibn.fm/jRa6y). The company’s strategy to retain and finance more of its energy assets appears to be taking shape, reflected in a significant increase in IPP revenue and asset growth during the fiscal year ended June 30, 2025.

While total revenues fell 29% to C$41.5 million (US$ 29.76 million), PowerBank’s IPP segment grew exponentially, posting C$9.3 million (US$ 6.67 million) compared to just C$0.6 million (US$ 0.43 million) in FY 2024, a 1,508% jump. The company’s gross margin also improved to 25% from 20%, indicating higher margins from IPP operations.

Total current assets climbed to C$41.3 million (US$ 29.61 million), up from C$17.6 million (US$ 12.62 million) a year earlier. The growth was fueled by the expansion of the IPP portfolio, new project financing agreements, and an increasingly diverse pipeline of renewable energy developments.

PowerBank ended FY 2025 with C$14.9 million (US$ 10.68 million) in cash, restricted cash, and short-term investments. The company also raised approximately US$8.5 million through a registered direct offering and could potentially secure an additional US$10.65 million if all related warrants are exercised.

PowerBank’s management has emphasized that FY 2025 was a transition year. The acquisition of Solar Flow-Through Funds Ltd. (“SFF”) early in the year, valued at up to C$45 million (US$ 32.27 million), added 29 MW of operating assets and set the foundation for sustained, recurring income streams.

“PowerBank’s strategic focus is growing its independent power producer asset base, creating long term revenues for years to come,” said Dr. Richard Lu, PowerBank’s president and CEO. “This means more projects retained and a longer cycle as PowerBank works to finance these assets to retain ownership.”

A potential catalyst for PowerBank’s growth is its announced financing with CIM Group, which provides for up to US$100 million in project-based financing. The funds, once the transaction closes, will support a portfolio of up to 97 MW of solar projects in the U.S., helping accelerate PowerBank’s goal of scaling its IPP base without diluting shareholders.

The company’s development pipeline now spans 942 MW of solar PV and 864 MWh of battery energy storage system (“BESS”) capacity, a combined 1,806 MW/MWh of potential future assets. These projects are divided into operational, under construction, advanced development, and early-stage development phases, providing a clear roadmap for future growth.

Among its deals completed during the financial year, PowerBank entered an agreement with Qcells to sell and build four ground-mounted solar projects in upstate New York totaling 25.6 MW. The combined value of the sale and EPC contracts is approximately US$49.5 million, with PowerBank expected to retain operations and maintenance contracts after completion. Two of these projects have already begun construction and two remain subject to permitting.

PowerBank continues to develop multiple BESS projects in Ontario, two of which are supported by a C$25.8 million (US$ 18.50 million) project finance facility from the Royal Bank of Canada. The SFF-06 project, featuring a 4.99 MW BESS, is already under construction and expected to begin operations by year-end and the other project (903) remains in permitting.

The company also reported delays in the permitting process for other Ontario projects (OZ-1 and 903 (noted above)), citing ongoing municipal reviews and appeals. PowerBank has filed force majeure notices to preserve its rights under existing contracts and continues to work through planning and approval challenges.

Beyond traditional solar and storage, during the fiscal year PowerBank announced its intent to enter the data center energy supply market. While still exploratory, the company said it is in discussions with potential partners and customers as it evaluates opportunities to provide power infrastructure to this rapidly expanding sector.

PowerBank is positioning itself to become a more stable, cash-generating independent power producer. Its participation in programs such as Nova Scotia’s Community Solar initiative, which recently granted three of the projects it is developing for a third party a total of C$1.74 million (US$ 1.25 million) in funding, adds another layer of regional diversification.

Dr. Lu noted that new U.S. incentives under the “One Big Beautiful Bill Act” have created an opportunity to fast-track projects qualifying for full investment tax credits. Combined with PowerBank’s activity under Canada’s IESO Long-Term RFP framework, the company appears to be laying the groundwork for sustained growth.

“The company has prioritized development pathways in key U.S. states where site control, interconnection progress, and permitting are sufficiently advanced to qualify for full ITC treatment under the new rules. In parallel, PowerBank’s diversified footprint across Canada offers resilience against U.S. policy risk. The company is currently deploying battery storage systems in Ontario under the Independent Electricity System Operator’s (‘IESO’) Long-Term RFP framework, which is designed to secure clean, dispatchable capacity through decade-long contracts,” Dr. Lu explained. “PowerBank is also a leader in Nova Scotia’s Community Solar program, where it holds significant market share and is actively expanding.”

For more information, visit the company’s website at https://PowerBankCorp.com.

This report contains forward looking information. Please refer to the press releases entitled “PowerBank Announces Fiscal Year End Results” and dated October 2, 2025, for additional details on the information, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• The closing of the public offering provides the company with critical financial flexibility as it continues to advance its pipeline of products.
• The $7.5 million raised through the public offering is particularly significant in the context of Soligenix’s ongoing clinical development programs.
• SNGX notes multiple potential value drivers over the next 18 months, including clinical milestones, regulatory interactions and data readouts across its pipeline.

Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring that the company has the financial resources to reach key inflection points across its portfolio, including late-stage clinical trials and regulatory milestones. The move underscores Soligenix’s commitment to advancing therapies for rare diseases where there is significant unmet medical need.

The successful closing of the public offering provides Soligenix, a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with critical financial flexibility as it continues to advance its pipeline of orphan and fast-track designated products (https://ibn.fm/3ZF0q). The company’s portfolio includes treatments for cutaneous T-cell lymphoma (HyBryte(TM) or “SGX301”), mild-to-moderate psoriasis (“SGX302”), Behçet’s disease (“SGX945”) and oral mucositis in head and neck cancer (“SGX942”), as well as several vaccines for emerging infectious diseases. According to the company, these assets represent multiple potential value drivers, with combined estimated global market potential exceeding $2 billion annually.

The $7.5 million raised through the public offering is particularly significant in the context of Soligenix’s ongoing clinical development programs. For HyBryte, the company is conducting a confirmatory phase 3 multicenter, double-blind, placebo-controlled study with approximately 80 patients diagnosed with early-stage cutaneous T-cell lymphoma (“CTCL”). The funding ensures that this pivotal study, as well as related regulatory engagements with the U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”), can continue uninterrupted through 2026. HyBryte has already demonstrated positive phase 3 results, and the confirmatory trial is a critical step toward potential commercialization and the broader availability of this first-in-class therapy for a rare patient population.

Beyond HyBryte, the funding provides Soligenix with the resources to advance its other high-potential pipeline candidates. SGX302, a therapy for mild-to-moderate psoriasis, is in phase 2a testing, and SGX945, targeting Behçet’s disease, has completed a phase 2a proof-of-concept study. Both programs represent substantial commercial opportunities in areas of unmet need, with estimated global market potential of more than $1 billion for psoriasis and more than $200 million for Behçet’s disease. By securing additional capital, Soligenix positions itself to execute these studies efficiently while maintaining strategic flexibility to pursue additional development or partnership opportunities.

The company notes multiple potential value drivers over the next 18 months, including clinical milestones, regulatory interactions and data readouts across its pipeline. These events are expected to provide a series of inflection points that could materially enhance the company’s valuation. The public offering allows Soligenix to maintain momentum across these programs, reducing the risk of delays due to funding constraints and ensuring that development timelines remain on track.

Strategically, extending the company’s cash runway through 2026 is crucial for both operational stability and investor confidence. It allows Soligenix to navigate the final stages of pivotal trials, prepare for potential product launches and continue discussions with regulatory agencies without the immediate need to secure additional capital. This financial security is particularly valuable in the rare disease space, where clinical programs can be resource-intensive and timelines for regulatory approval are tightly linked to sustained funding. For investors, this funding round reinforces Soligenix’s commitment to delivering on its growth strategy while protecting shareholder value.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Silver prices have surged more than 60% this year, nearing the all-time high of $49.45 per ounce. 
• Gold prices have surged roughly 53% this year, reaching new all time highs of over $4,000 per ounce.
• In addition to strong investment appetite, industrial demand, particularly from solar and EV sectors, underpins silver’s long-term fundamentals.
• New Pacific’s Silver Sand and Carangas (starter pit) projects in Bolivia could yield nearly 19 million ounces of silver annually. 
• Carangas also has significant gold potential, strengthening project economics amid high prices, as gold reached record highs above $4,000.
• Bolivia’s October 19 presidential runoff may open the door for more foreign mining investment.

Silver prices climbed past $48 an ounce in early October, up well over 60% year-to-date and approaching the 1980 record of $49.45 (https://ibn.fm/vo2aL). The impressive surge is driven by both macroeconomic and structural factors: persistent inflation, growing industrial demand from renewable energy and electronics, and global uncertainty that is pushing investors into safe haven assets like precious metals (https://ibn.fm/t4d1l).

Industrial use is key to the growing demand and price surge. Silver demand in solar panels and electric vehicles has reached record levels, with projections that renewable infrastructure will consume more silver by 2050 than has been mined over the last five centuries. This dual role, as both an industrial and monetary asset, distinguishes silver from other commodities.

Against this backdrop, New Pacific Metals (NYSE American: NEWP) (TSX: NUAG), a Canadian exploration and development company, is drawing investor attention. The company has projects in Bolivia, Silver Sand and Carangas, that stand out as two of the largest undeveloped silver deposits globally. Together, they are projected to produce nearly 19 million ounces annually when developed.

Bolivia offers opportunity but comes with challenges. From Cerro Rico in Potosí, one of the richest deposits in history, to today’s underexplored highlands, the country remains mineral-rich. The country is the world’s fourth-largest silver producer, accounting for 5% of global supply in 2024. Yet more than 60% of its territory remains underexplored. Geological potential is significant, but slow permitting has deterred foreign capital.

The upcoming presidential runoff on October 19 could mark a turning point. The ruling MAS party, dominant for two decades, lost in August elections. Both remaining candidates have signaled greater openness to foreign investment. For companies like New Pacific, it could unlock the ability to move key projects forward.

If investment conditions improve following the election, New Pacific’s projects could help Bolivia reclaim its historical role as a central player in global silver supply, while offering shareholders leverage to one of the most dynamic commodities of 2025.

Silver Sand is the company’s flagship in Bolivia, with potential annual production of 12 million ounces. Carangas adds at least another 6.6 million ounces of silver a year over 16 years under its preliminary economic assessment, which focused on starter pit within a much larger resource. At $24 silver, Carangas economics are already strong, with a post-tax NPV5% of $501 million, an internal rate of return of 26%, and a 3.2-year payback period. All-in sustaining costs are projected at $7.60 per ounce. With silver prices now over $48 an ounce, the project’s leverage to rising prices is substantial, highlighting its strong economic potential.

What makes Carangas more compelling is its gold upside. Exploration indicates over 1.3 million ounces of gold potential at depth, not yet included in the PEA. With gold trading above $4,000, the addition of gold credits could substantially enhance project economics and offer a hedge if silver prices consolidate. On October 8, gold reached a new record price of $4,050 an ounce, marking a 53% increase so far this year (https://ibn.fm/l5JoT).

For more information, visit the company’s website at www.NewPacificMetals.com/welcome.

NOTE TO INVESTORS: The latest news and updates relating to NEWP are available in the company’s newsroom at https://ibn.fm/NEWP

• Lantern’s RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies.
• Dr. Schalop reflects on lessons from developing ONC201, approved for H3K27M-mutant glioma, after a 16-year journey.
• Both leaders highlight the potential for AI to accelerate regulatory reviews and clinical trial design.
• The conversation underscores how AI could reduce oncology drug timelines and costs, improving patient access to new treatments, and how STAR-001, Lantern’s new CNS cancer drug, can benefit from these AI-driven insights.

In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of dollars. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, aims to challenge that timeline. 

In a recent discussion titled “From Discovery to Clinical Trials to Patients: Key Decisions Shaping Novel CNS Oncology Medicines,” Lantern CEO Panna Sharma and new board member Dr. Lee Schalop, co-founder of Oncoceutics and a key figure behind the development of ONC201 (dordaviprone), explored how data science and machine learning could shorten the journey from lab to clinic in central nervous system (“CNS”) oncology (https://ibn.fm/vC0Ma).

Dr. Schalop, who began his career on Wall Street before earning a medical degree in his 40s, said his unique background helped him bridge science and strategy. “I realized I could probably do more by combining my business background with my new medical knowledge,” he said. That blend of experience ultimately led him to co-found Oncoceutics, where ONC201 became one of the first drugs approved for H3K27M-mutant glioma, a rare and aggressive brain cancer. Now joining Lantern’s board, Schalop brings both a cautionary and optimistic view of how the next generation of CNS drugs can be developed faster and smarter, especially through the use of artificial intelligence.

ONC201’s development began with phenotypic screening: testing compounds for general anti-cancer activity without knowing their mechanism of action. Working with the Broad Institute, Schalop’s team discovered that the molecule showed particular efficacy against brain cancer.

However, identifying the precise genetic context (the H3K27M mutation) took years of additional preclinical and clinical work. The breakthrough came during a Phase 2 trial at Harvard, when one patient’s tumor disappeared. That patient, it turned out, was the only one with the H3K27M mutation. “An AI-type program would have known about this, because it was known at this time, although just not well known,” Schalop said. “And it would have immediately put the pieces together and said, ‘Aha, this patient had it, no one else did. This is where you should devote your effort.’”

Sharma agreed that machine learning systems could have accelerated those insights. Lantern’s own platform, RADR(R) is designed to perform precisely that function. Built to analyze vast genomic and clinical datasets, RADR(R) identifies which cancer subtypes and mutations are most likely to respond to specific compounds. The platform supports Lantern’s three lead drug candidates and an antibody-drug conjugate (“ADC”) program across 12 cancer indications.

For Sharma, the promise of AI isn’t just speed, but accuracy and the ability to select the right patient populations early and design smarter trials. He cited STAR-001, a Lantern program targeting CNS cancers, as a candidate that could follow a more efficient path than traditional drug development.

The discussion also turned to the U.S. Food and Drug Administration and how regulators might use AI to shorten the pre-review phase of drug approvals. Schalop explained that it took 16 years to get ONC201 from discovery to approval. Even if the FDA can shorten its review timeline, the real opportunity is to make the 10 years before that faster, he added.

Both speakers mentioned growing interest in artificial intelligence uses within the agency, as current commissioner Marty Makary has discussed using AI to process and analyze complex scientific submissions more efficiently. Sharma added that Lantern is already deploying AI internally to summarize trial data in hours rather than weeks. “Scientific review and biomedical literature review and data review and analysis take a long time for humans to do well,” he said. “If you can get systems to do it even better and do it within minutes, as opposed to weeks or months,” that is a real game changer.

Oncoceutics’ lean approach (roughly $25 million in equity and a similar amount in grants) kept control in the founders’ hands but extended the timeline. Eventually, the company was acquired by Chimerix and later by Jazz Pharmaceuticals, which brought ONC201 to approval at a total cost of around $300-$400 million.

By contrast, AI-assisted development could lower both timelines and costs. Identifying optimal indications early reduces the number of unsuccessful trials, while predicting effective combinations may limit expensive exploratory work.

Schalop noted that AI could also make combination trials more feasible: “If you can figure out how something will probably work, as opposed to might work, it will be worth spending the time and money to try that combination.”

Both Sharma and Schalop emphasized that the ultimate goal of these technologies is to improve outcomes for patients with rare, hard-to-treat cancers. Each year, roughly 2,000 U.S. patients are diagnosed with H3K27M-mutant glioma, the same group now eligible for ONC201 treatment.

For Sharma, the message is clear: oncology’s future depends on integrating clinical experience with data science. “I think it’s a great time to be in medicine. There’s just so much data and people are publishing so much. It’s an exciting time. And hopefully it translates more and more into better patient outcomes,” he concluded.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• Red Cat Holdings is partnering with Safe Pro Group Inc. (NASDAQ: SPAI) to outfit drones with AI threat detection technology.
• This technology, called Safe Pro Object Threat Detection (“SPOTD”), helps drones identify and locate various kinds of dangerous explosive hazards in real time.
• The technology has already performed ample real-world analysis, with more than 2 million images processed and over 36,000 landmine and unexploded ordnance (“UXO”) detected.

Safe Pro Group (NASDAQ: SPAI), a mission-driven technology company that delivers AI-powered security solutions, recently collaborated with Red Cat Holdings to embed AI threat detection into Red Cat’s Black Widow(TM) drones (https://ibn.fm/NXv7N).

The move has generated market attention for Red Cat, as SPAI’s technology enables the drones to identify and find explosive threats in real-time. The Black Widow(TM) will also integrate with Safe Pro’s new SPOTD Navigation, Observation and Detection Engine (“NODE”), a powerful, edge-based solution designed to process, map and share mission critical information collected by drones. This appeals to both military and security clients, and lets teams on the ground navigate dangerous terrain and environments in a safer way.

The AI threat detection capabilities of the drones are powered by Safe Pro Object Threat Detection (“SPOTD”), a technology that was developed for the modern battlefield, where personnel on the ground are exposed to various small and difficult-to-see threats.

This patented drone-based imagery analysis platform is able to see and identify more than 150 threats such as landmines, UXO, and cluster munitions. The technology is battle-tested, and has nearly three years of real-world usage in Ukraine. 

Throughout this time, it has processed over two million images, analyzed more than 28 TB of data, detected more than 36,000 landmines and UXO, and has surveyed over 9166 hectares (more than 22,600 acres) of land.

In addition to this large dataset of landmines and UXO, SPOTD features AI algorithms that are trained to recognize threats. It accurately labels and tags landmines and UXO that can then display the results on high-resolution maps to give teams a birds-eye view of their surroundings to improve safety and situational awareness.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group (NASDAQ: SPAI) is a technology company that’s delivering advanced and cutting-edge AI-powered defense and security solutions. The company’s AI image technology enables real-time detection of various threats, is already operating at scale, and has more than two years of real-world usage so far.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• Micropolis Holding Co. (NYSE American: MCRP) has joined NVIDIA’s Inception Program, gaining access to the company’s advanced AI and robotics technologies.
• NVIDIA GPUs and Orin edge computing modules now serve as the core processing units for Micropolis autonomous robots.
• The partnership integrates NVIDIA Omniverse and Isaac Sim to create digital twins for simulation, testing, and validation of AI systems.
• Collaboration strengthens the position of Micropolis as a UAE-based robotics developer with global ambitions.
• The announcement follows Micropolis’s expansion into Egypt and North Africa through an exclusive distribution agreement with AERXIO.

Micropolis Holding (NYSE American: MCRP), a pioneer in unmanned ground vehicles (“UGVs”) and AI-driven security solutions, announced its membership in NVIDIA’s Inception Program, a global initiative designed to accelerate AI-driven innovation. The collaboration embeds NVIDIA’s GPU and simulation technologies deep within Micropolis’s robotics ecosystem, enhancing the performance, safety, and adaptability of its autonomous platforms.

As part of the partnership, Micropolis is integrating NVIDIA’s GPUs and Orin edge computing modules into its unmanned ground vehicles. These systems handle core robotic functions, including perception, decision-making, and navigation, directly onboard rather than through cloud servers.

By processing data in real time, the robots can detect objects, plan paths, and predict environmental behaviors with low latency. This enables safe and efficient operation even in bandwidth-limited or remote settings such as industrial sites, border zones, and urban environments.

According to Micropolis, deploying AI models on the Orin platform allows its autonomous vehicles to achieve faster response times and improved reliability. 

Micropolis also uses NVIDIA’s Omniverse and Isaac Sim platforms to simulate and validate its robotics systems before field deployment. Through these digital twin environments, engineers can model real-world conditions, test AI algorithms, and assess system behavior under varying parameters.

This simulation capability reduces the need for costly or risky real-world testing while accelerating design cycles. It also allows the company to validate its systems against large-scale scenarios, from crowded urban intersections to complex terrain navigation, that would otherwise be impractical to replicate.

Together, these technologies form the digital backbone of Micropolis’s AI and robotics platform. They enable the company to develop, test, and refine autonomous systems designed and built in the UAE for deployment across global markets.

“Our partnership with NVIDIA not only ensures the technological success and longevity of our products, but also provides a strong foundation for our future scale-up milestones,” the company said in a statement. “By building on NVIDIA’s world-class AI and robotics ecosystem, Micropolis is positioned to lead the next generation of intelligent, autonomous solutions, made in the UAE for the world.”

The NVIDIA partnership comes shortly after Micropolis announced an exclusive distribution agreement with AERXIO FZ-LLC, a UAE-based technology provider. Under the deal, AERXIO gains sole rights to distribute Micropolis’s unmanned ground security vehicles across Egypt and North Africa (https://ibn.fm/KBXxq).

Central to the rollout is “The Patrol,” Micropolis’s flagship autonomous platform engineered for desert and border operations. Capable of speeds up to 50 km/h and a 15-hour runtime, the UGV is equipped with Microspot AI software for real-time perception and situational awareness.

Two of the initial deployments are expected in Egypt, with additional rollouts planned across the wider North African region. The collaboration gives Micropolis access to AERXIO’s network of government and industrial partners, aligning with regional initiatives to modernize infrastructure and security operations using AI-driven systems.

Specializing in UGVs, modular robotics platforms, and AI systems aimed at sectors such as defense, logistics, and smart infrastructure, Micropolis has cultivated relationships with major public-sector clients in the Gulf Cooperation Council region, including Dubai Police, which has supported the testing and integration of autonomous security solutions.

The firm’s modular design approach enables scalability across applications, from perimeter patrol and urban inspection to industrial transport and emergency response. By building a unified architecture for both hardware and software, Micropolis can adapt its systems for different missions while maintaining centralized control through its AI management layer.

The combination of NVIDIA’s hardware acceleration and simulation platforms positions Micropolis to scale production and deploy AI robotics systems in global markets. The company’s expansion into North Africa further extends its reach into markets investing heavily in smart infrastructure and surveillance technology. In Egypt, ongoing digital transformation initiatives and increased border surveillance spending create conditions conducive to adoption of UGV technologies.

For more information, visit the company’s website at www.Micropolis.ai.

NOTE TO INVESTORS: The latest news and updates relating to MCRP are available in the company’s newsroom at https://ibn.fm/MCRP

• The Nevada Titan Project is a flagship, district-scale asset with multiple deposit styles, high-grade copper assays, and clear porphyry-skarn potential.
• Fairchild’s pending acquisition of the Golden Arrow Project could add a resource-stage gold-silver asset to the portfolio upon closing.
• The Fairchild Lake Property provides a second, 100%-owned exploration opportunity in Ontario’s underexplored Savant Lake belt.
• The company is advancing its projects using AI-integrated geophysics, drone magnetics, and modern geochemical analysis to accelerate targeting.
• Fairchild’s leadership team brings deep experience in geology, policy, capital markets, and mine development across global jurisdictions.

Fairchild (TSX.V: FAIR) is a mineral exploration company focused on acquiring, exploring, and developing high-quality mineral properties in mining-friendly jurisdictions across North America. The company targets projects with historical production, strong multi-metal potential, and clear pathways to discovery through modern geoscience, AI integration, and responsible development practices.

Fairchild’s portfolio is anchored by the Nevada Titan Project, a district-scale, copper-gold system located just outside Las Vegas in the prolific Walker Lane Belt. The company has also entered into an MOU to acquire the advanced-stage Golden Arrow Project in Nevada, subject to completion of a definitive agreement, and it holds 100% ownership of the Fairchild Lake Property in Ontario.

Fairchild’s mission is to build long-term value by identifying overlooked mineralized systems and unlocking their potential using modern exploration methods.

The company is headquartered in Vancouver, British Columbia.

Projects

Nevada Titan Project (Goodsprings District, Nevada)

Nevada Titan is Fairchild’s flagship asset and a district-scale, multi-metal opportunity located just 55 kilometers southwest of Las Vegas. Spanning over 6,150 acres (300+ claims), the project sits within the historically productive Goodsprings Mining District—part of the prolific Walker Lane Belt and Battle Mountain Trend extension. The area hosts numerous historic mines, including Copperside, Copper Chief, Azurite, and Fitzhugh Lee, yet remains largely untested by modern drilling.

Surface sampling and geological mapping have confirmed high-grade copper mineralization up to 34.0% Cu, with associated values of gold, silver, molybdenum, and platinum group elements. A 1.5-kilometer copper-gold corridor has been identified, showing pods and lenses of mineralization consistent with a porphyry-skarn-CRD system. Notably, the discovery of a hydrothermal breccia pipe with garnet-bearing skarn textures and elevated molybdenum signals a porphyry-affiliated source at depth.

Ongoing exploration includes drone magnetics, AI-integrated targeting, and induced polarization geophysics. With infrastructure already in place and proximity to Las Vegas contractors, Fairchild is preparing for a 2026 drill campaign focused on unlocking the project’s large-scale copper-gold system.

Golden Arrow Project (Walker Lane Shear Zone, Nevada)

In September 2025, Fairchild signed a Memorandum of Understanding to acquire 100% of the Golden Arrow Project, an advanced-stage gold-silver asset in Nevada’s Walker Lane Trend. The project hosts a historic mineral resource estimate of approximately 347,000 ounces of gold and 5.3 million ounces of silver, including 296,500 ounces of gold and 4.0 million ounces of silver in the measured and indicated categories. According to third-party analysis by mining analyst Ryan D. Long, the total acquisition consideration of $5.0 million equates to approximately $12 per ounce of gold in the ground.

The project’s two main deposits, Gold Coin and Hidden Hill, were historically mined at surface and remain open at depth, supported by over 61,000 meters of past drilling. Modern geophysical work has outlined 34 additional exploration targets, including six classified as high-priority. Hosted in a volcanic complex with both high-grade vein and disseminated mineralization, the system offers strong potential for expansion.

Golden Arrow is situated just 96 kilometers from Kinross’s 28-million-ounce Round Mountain Mine and expands Fairchild’s Nevada footprint by 170% when combined with the Titan Project. The project’s extensive exploration database and near-surface deposits make the acquisition a compelling strategic entry point into a proven district with significant near-term development potential.

Fairchild Lake Property (Savant Lake Greenstone Belt, Ontario)

Fairchild Gold holds 100% ownership of the Fairchild Lake Property, a 2,224-hectare claim package in Ontario’s underexplored Savant Lake greenstone belt. Historical and recent work, including airborne geophysics and soil sampling, has identified anomalous gold values near the Kashaweogama Lake Fault, a major crustal break. The company draws geological comparisons to Red Lake’s LP Fault and views the structural setting as a promising focus for future exploration.

Market Opportunity

Fairchild operates in Tier-1 mining jurisdictions where political stability, established infrastructure, and clear permitting pathways reduce development risk and enhance long-term value. Nevada, in particular, is a top-ranked global destination for mineral exploration and home to some of the world’s most productive gold and copper belts. Fairchild’s flagship project, Nevada Titan, is located in the Walker Lane Belt, a prolific trend responsible for more than 89 million ounces of gold and nearly 1 billion ounces of silver to date.

The company is strongly positioned to benefit from the ongoing historic bull market in gold. In early October 2025, Goldman Sachs raised its December 2026 gold price forecast to $4,900 per ounce, citing strong ETF inflows and sustained central bank demand. A Jefferies analyst has projected gold could reach $6,600 per ounce in the near term, while other major institutions including UBS and Bank of America have also raised their targets amid elevated geopolitical risk, structural reserve diversification, and anticipated U.S. rate cuts. With limited new supply and rising demand from both institutional and retail investors, gold remains a cornerstone of portfolio hedging and upside exposure.

Copper also remains a core strategic focus, with demand expected to double by 2035, driven by electrification, grid modernization, and clean energy buildout, according to S&P Global. The Nevada Titan Project hosts porphyry-style copper-gold mineralization, along with skarn and carbonate replacement features—deposit types that are key global sources of both industrial and precious metals.

Leadership Team

Nikolas Perrault, CFA, Executive Chairman, brings over 35 years of experience in capital markets, securities trading, and strategic advisory roles. He began his career with Canada’s top financial institutions and has since focused on guiding small to mid-cap companies through public listings, M&A, and capital raising. He holds a Chartered Financial Analyst designation and a Bachelor of Commerce.

Luís Martins, President and CEO, brings over 40 years of experience in the exploration and mining sector. He previously served as Director of the Mineral Resources Department at Portugal’s Geological Survey and as Director of Mines and Quarries at the Directorate-General of Energy and Geology. He has coordinated international working groups focused on raw materials and mineral policy and has authored more than 100 scientific publications.

Dr. Sergei Diakov, Chair of the Technical Committee and Senior Advisor, is a globally recognized geologist and former discovery lead at both BHP and AngloGold Ashanti. His track record includes major copper-gold discoveries such as Oyu Tolgoi in Mongolia and Nuevo Chaquiro in Colombia. Dr. Diakov brings decades of senior experience managing exploration teams, overseeing risk across geologic and ESG domains, and executing discovery-driven development strategies.

Adam Cavise, Independent Director, brings over 25 years of capital markets experience and has been directly involved in structuring and closing more than $100 billion in public and private equity offerings, SPACs, and recapitalization transactions. Currently a partner at Revere Securities in New York, he has held senior equity roles at Kingswood, Spartan Capital, and Macquarie, and is well regarded for his deep Wall Street network and leadership in equity capital markets.

Fairchild Gold benefits from a deeply experienced leadership and advisory team with expertise across exploration, capital markets, and corporate development. To view the full team, click here.

For more information, visit the company’s website at www.FairchildGold.com.

NOTE TO INVESTORS: The latest news and updates relating to FAIR are available in the company’s newsroom at https://ibn.fm/FAIR

• The expansion of Soligenix’s European Medical Advisory Board underscores the company’s commitment to delivering innovative treatment options to European patients.
• HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer.
• The company’s efforts could establish HyBryte as a new standard of care for patients who currently have limited options.

Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial unmet medical need, particularly in early-stage patients who often have limited treatment options. Addressing this gap, Soligenix (NASDAQ: SNGX) recently announced the expansion of its European Medical Advisory Board (“MAB”) (https://ibn.fm/6354Y) to provide additional clinical and strategic guidance as the company advances its confirmatory phase 3 study (referred to as FLASH2) evaluating the safety and efficacy of its proprietary CTCL treatment: HyBryte(TM).

The expansion of Soligenix’s European MAB underscores the company’s commitment to delivering innovative treatment options to European patients. The announcement also notes a strategic step to ensure the successful execution of FLASH2 and to navigate the complex regulatory and clinical landscape across European countries.

By bringing together leading experts in dermatology and oncology, the board will provide critical insights into clinical development, regulatory compliance, and market access strategies. This collaboration will help align Soligenix’s development plans with the unique needs of European patients and healthcare providers, ensuring that HyBryte’s advancement is guided by both scientific rigor and practical considerations for real-world application.

HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer. When applied topically and activated by visible light, it targets malignant T-cells within lesions while sparing surrounding healthy tissue. Soligenix’s initial phase 3 FLASH study successfully achieved its primary endpoint and demonstrated a 49% response rate at 18 weeks of treatment in patients with early-stage CTCL, providing strong evidence of its potential clinical benefit (https://ibn.fm/Yl6JC). Building on these findings, the ongoing FLASH2 study is a randomized, double-blind, placebo-controlled, multicenter trial enrolling approximately 80 patients. It aims to confirm and extend previous results, evaluating the therapy’s efficacy and safety during an 18-week treatment period, with top-line results expected in the second half of 2026.

Looking ahead, Soligenix’s initiatives with HyBryte have the potential to significantly impact CTCL treatment in Europe. By focusing on early-stage disease with a localized, non-invasive therapy, the company aims to offer effective disease control while minimizing side effects, a combination rarely seen in current treatment regimens. The European MAB expansion further strengthens Soligenix’s ability to deliver on this promise, providing expertise to guide clinical execution, regulatory strategy, and patient access. Combined with the results of the FLASH2 trial, these efforts could establish HyBryte as a new standard of care for patients who currently have limited options.

Soligenix’s work on CTCL also reflects a broader commitment to addressing rare and underserved diseases. By leveraging innovative therapeutic approaches and expert guidance, the company is positioning itself to improve both clinical outcomes and patient quality of life. With a clear pathway for near-term clinical validation and strategic advisory support in Europe, Soligenix is not only advancing its pipeline but also addressing a critical gap in oncology care. These efforts demonstrate the company’s dedication to providing meaningful, effective and accessible treatment options for CTCL patients across Europe.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX